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1. Introduction
Mycobacterium tuberculosis is the world’s most successful pathogen, having survived over
70,000 years and currently infecting nearly 2 billion people worldwide [1]. With around 9
million new cases of tuberculosis (TB) each year, almost one third of the population is at risk
for developing active disease [2]. In 2012 alone, an estimated 3,500 people per day died of TB
and, in fact, human immunodeficiency virus (HIV) is the only other infectious disease
responsible for more deaths each year than M. tuberculosis [1, 3]. Because of these deadly
statistics, the World Health Organization (WHO), the Centers for Disease Control (CDC), and
the Bill and Melinda Gates foundation, among many others, have committed to eradicating
M. tuberculosis by the year 2050. A combined strategy of drug treatment, better diagnostics,
and prevention (i.e. vaccine development) is the only way to reach this goal [4].
While finding a cure and treating the disease is an essential aspect of medicine, of equal
importance are prevention measures to stop contracting the disease in the first place. Because
extreme and totally drug resistant strains of M. tuberculosis are appearing with increasing
frequency, it is essential that we block the spread of this pathogen by developing a vaccine
that provides protection against infection.
1.1. Vaccine development
The hallmark of an effective vaccine is one that can be given to a young population, with no
adverse side effects, and which will provide lifelong immunity against a particular pathogen.
The basis of a functional vaccine is dependent on the immune system’s ability to ‘remember’
an encounter with a foreign pathogen. Typically, immunological memory is established upon
the first encounter with a pathogen by the creation of memory T cells. These memory T cells
are specific to a particular antigen and will reside in tissues and lymph nodes until they
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recognize their specific pathogen and become activated. Upon activation by a second exposure,
the memory T cells will quickly and efficiently initiate a response to eliminate the pathogen
and prevent disease. The creation of memory T cells and life-long immunity can be obtained
either by primary exposure to the pathogen followed by disease and eventual recovery, or by
being given a vaccine. Vaccines act to prime the immune system by exposing a person to a
non-lethal, milder version of the pathogen’s antigens so that those memory T cells can be
created without causing disease in the individual. Ideally, a vaccine is made of pathogen-
derived components that are critical for induction of protective immunity and consequently,
are often composed of either an attenuated (non-virulent) or killed version of the bacteria,
inactivated bacterial toxins, or subunits of the pathogen. The vaccines will have antigens
similar to the virulent version of the pathogen but would lack factors necessary for disease.
Thereafter, if a vaccinated individual is exposed to that particular set of antigens a second time,
the immune system will quickly eliminate the pathogen and prevent disease. The immune
system is therefore required to respond in a proper manner both to vaccination and to
subsequent challenges with the pathogen.
In the case of M. tuberculosis infection, however, the immune response initiated upon exposure
does not result in memory and instead, infection follows a more complex pathogenesis route.
The main route of transmission for M. tuberculosis is via aerosolization of liquid droplets
containing bacilli that are then breathed in by an individual. After inhalation, organisms are
carried into the deep lung where it is phagocytosed by antigen presenting cells (APCs), such
as macrophages or dendritic cells, which then travel to the draining lymph nodes and initiate
an immune response [1, 5]. M. tuberculosis specific T cells then migrate to the lungs and are
required for the formation of a granuloma around the site of infection [1]. In an immunocom‐
petent individual, this granuloma will contain the infection in the lungs and prevent active
disease [6] [1].
CD4+T cells are the hallmark of the immune response to M. tuberculosis infection and, together
with CD8+T cells play significant roles in the various stages of infection and disease [6, 7].
Interferon (IFN)-γ and tumor necrosis factor (TNF)-α are essential cytokines for the induction
of immunity to infection [6, 7]. Our understanding of the network of immune cells and
cytokines required by the host to contain the infection, generate granulomas, and limit the
extent of tissue involvement is increasing and will provide a better understanding of the
requirements for generating vaccine mediated immunity.
This chapter will focus on the varied and unique aspects of M. tuberculosis that have made the
development of a vaccine a challenging prospect. We will discuss the only vaccine currently
on the market, BCG, its history, and why it has failed to prevent the spread of this pathogen.
We will also discuss the various animal models and methodologies that are used by researchers
to study the immune response to M. tuberculosis in the hopes of developing a more effective
vaccine. We will also discuss a few of the vaccines that have already been developed and are
being tested in clinical trials. Additionally, we will briefly discuss the various regulatory
approval processes that are required to test a vaccine before it can finally be approved for
release on the market.
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2. The BCG vaccine
Bacillus Calmette-Guérin (BCG) is the most widely used vaccine having been delivered to
nearly 3 billion people [8-10]. Despite its widespread use, BCG delivers only minimal protec‐
tion and has failed to eradicate or reduce the disease burden of TB. The mechanisms by which
BCG works to provide its marginal protection are incompletely understood. Even though BCG
provides an imperfect defense against M. tuberculosis infection, it is still the best vaccine
available. In this section of the chapter we will discuss the history of BCG and some possible
reasons why it has failed to stem the tide of deaths due to M. tuberculosis infection.
2.1. History
Albert Calmette and Camille Guérin developed BCG at the beginning of the 20th century.
Developed from a virulent strain of Mycobacterium bovis, the BCG vaccine was attenuated by
serially passing the strains on potato slices supplemented with glycerol over a period of 13
years until a non-virulent strain was obtained [8-10]. Trials of the newly developed vaccine
were performed in cows, monkeys, and African apes and proved to be efficacious [11] [12].
The strain was first used as a vaccine in humans in 1921 with few adverse side effects observed
in the patients who received it [8, 9]. The non-virulence of this strain was then established
before it was sent out to several laboratories throughout the world and used as a vaccine. The
vaccine was then propagated in the various countries in different ways with varying passage
numbers, resulting in the emergence of different variants of the BCG vaccine [8, 10].
2.2. World use
BCG is very cheap to produce and at only $2-3USD per dose, it is one of the most cost effective
ways to provide at least partial protection against M. tuberculosis to millions of children
worldwide [13]. Most of the BCG given in the world is supplied by UNICEF – obtained from
three major sources; producers in Denmark, Japan, and Russia [8, 9]. Most countries around
the world require that the BCG vaccine be given during childhood. The US, Canada, and Italy
are some of the very few countries that have never required that children be given BCG. Most
of Europe and Australia did at some point in their history require BCG to be given to children,
but have since changed their policies. All of Africa, Asia, and most of South America currently
require BCG to be given in early childhood [14].
2.3. Safety and efficacy
A huge reason for the widespread use of BCG is that it is considered to be one of the safest
vaccines on the market [15]. Side effects of BCG are very rare with the most common compli‐
cation being swelling around the injection site [15]. The most significant issue to arise from
BCG vaccination is in HIV infected and other immunocompromised individuals. The increased
risk of dissemination in HIV infected children lead the WHO to change its policy and recom‐
mend that they not be given BCG [15, 16]. Even so, BCG is still part of the WHO’s expanded
program of vaccination [8].
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Studies into the efficacy of BCG have revealed wide-ranging results from vaccination programs
with some reports suggesting 80% efficacy and others showing no protection at all [15, 17].
BCG is thought to convey protection against dissemination of the mycobacteria to other organs
during childhood, an event that is highly fatal if left untreated. BCG does not, however, provide
protection against adult pulmonary disease, which is the main route by which M. tuberculo‐
sis is transmitted [16].
2.4. Variability in efficacy
There are several possible reasons behind the huge variability in the reported efficacy of BCG;
we will discuss some of these reasons in this section. It is important to keep in mind that some
of the issues surrounding BCG efficacy variability are also issues which apply to the new M.
tuberculosis vaccines currently being developed.
2.4.1. Variation in the strain of BCG that is used for vaccination
There are at least 11 different types of BCG vaccines currently available throughout the world
[8]. A major reason for the different types of BCG and the genetic variability between the strains
is mainly a product of the time period when the vaccine was developed. When Calmette and
Guérin first developed BCG, they sent it out to several other laboratories around the word.
Those laboratories cultured, grew, and stored BCG, each in their own way. It must be remem‐
bered that this occurred in the early part of the 20th century, before the advent of current
molecular techniques and storage methods that can maintain parent strain homogeneity.
Instead, as BCG was grown and cultured in these various laboratories, it accumulated a series
of independent mutations that continued to build upon themselves [8]. It was not until the
1960s, with the introduction of culture seed stocks that soon became the norm, that the
standardization of these lines became possible. By that time, however, the various strains of
BCG had diverged and modern analysis has demonstrated that there is significant variability
in the genetic make-up of these strains [8, 10]. The genetic variation in BCG strains can lead to
variation in how well they protect against infection due to difference in the cell surface proteins
that would elicit an immunogenic response [10]. However, all of these BCG strains have
remained non-virulent and a commonality among all of the strains is the loss of the ESX-1
excretion system. It is still not completely understood how the loss of the ESX-1 system blocks
virulence since its re-addition to at least two separate BCG strains does not restore virulence
back to wild type levels [10, 18]. Due to this variation in BCG strains, it is essential that accurate
record keeping be in place when conducting efficacy studies for the vaccine [8].
2.4.2. The genetic diversity of the tested population
The genetic diversity of a population can affect the outcome of any clinical research study and
this is an important factor to consider when examining vaccine efficacy. Various single
nucleotide polymorphisms (SNPs) within a genome can affect a person’s susceptibility to
disease and how their immune system responds to a vaccine. The spectrum of immune system
responses to a vaccine can vary from no response to complete activation and protection.
Variations within a person’s genome could prevent their immune system from properly
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responding to the vaccine and therefore it would not convey protection when the person is
exposed to the pathogen. For instance, it has been found that mutations in the IFN-γ receptors
leads to an increased risk of developing disseminated disease from BCG vaccination rather
than protection from M. tuberculosis infection [19]. Individuals with mutations in these
susceptibility genes are also more prone to infection by non-virulent, environmental myco‐
bacteria as well [19] [19].
Therefore, it is essential when designing a vaccine study in humans to have a large population
that is statistically powerful enough that some variability in immune response will not skew
the data. Additionally, no matter where a study is being conducted, the genetic diversity of
the population must be considered. An ethnically homogenous population is more desired for
a research study since that population will be more likely to share SNPs, and therefore more
likely to respond to a vaccine in a similar manner. It also follows that it may also be useful to
test multiple ethnic groups; indeed, some studies have suggested that the reason some vaccine
trails show high protection with BCG is because they were conducted within certain popula‐
tion groups [15].
2.4.3. Pre-vaccination exposure to the pathogen
Another issue that is of huge importance when conducting vaccine efficacy tests is whether or
not an individual has been pre-exposed to the pathogen. The immune response of an individual
who has already been exposed may be quite different than someone without prior exposure.
Especially in areas where TB is endemic, it is likely that a child will have already been exposed
to M. tuberculosis prior to vaccination [1]. A child could be exposed to both M. tuberculosis in
the form of infected adults, or to environmental nontuberculous mycobacteria (NTM) – both
of which could alter how that child responds to a vaccine. Some studies have also suggested
that pre-exposure to NTM may provide some protection that cannot be improved upon by
BCG delivery [9, 15, 20]. This may indeed be the case with BCG as it has been found that vaccine
programs with the highest degree of efficacy are those with more rigorous screening to only
include children who had not been previously exposed to the antigen [17].
2.4.4. Inaccurate diagnostic methods
Because of the complications that result from pre-exposure to the pathogen, it is essential
to have accurate diagnostic methods available when deciding which individuals to include
in a study. A non-homogeneous population (a mixture of non-and pre-exposed individu‐
als)  can  produce  misleading  results  that  can  hinder  accurate  interpretation  of  vaccine
efficacy.  In  the  case  of  M.  tuberculosis,  current  diagnostic  methods  are  often  slow  or
inaccurate. One of the most common diagnostics for M. tuberculosis is the tuberculin skin
test (TST), a delayed-type hypersensitivity reaction to protein purified from M. tuberculo‐
sis and injected just below the skin [21, 22]. It takes two to three days after injection of the
purified protein derivative (PPD) before the results can be read; a delay that can result in
loss of study participant compliance or even exposure. Additionally, the TST, as well as
many new serological tests, cannot distinguish between exposure to environmental NTM
and  infectious  M.  tuberculosis  [23].  Newer  IFN-γ  release  assays  (IGRAs)  are,  however,
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becoming  more  commonly  used  for  research  studies  since  they  are  selective  for  M.
tuberculosis  and  are  more  sensitive  than  the  TST  [21,  22].  IGRAs  are  in  vitro  tests  that
stimulate T cells with M. tuberculosis specific antigens (such as ESAT-6), if the T cells have
been previously exposed to these antigens, they will release IFN-γ [22].
3. Specific difficulties associated with M. tuberculosis vaccine
development
The complications involved with studying M. tuberculosis in a laboratory are numerous and
range from the practical to the scientific. Due to the complex nature of the pathogen, M.
tuberculosis presents some very unique challenges for the researcher studying it. In this section
we will go into more depth as to the specifics of these challenges and how they have delayed
the development of a vaccine.
3.1. Biosafety considerations
When a researcher decides to investigate the development of a vaccine against M. tuberculo‐
sis one of the very first considerations that must be taken into account is the safety of those
working with the pathogen. In the United States, the CDC provides a set of guidelines for the
safety measures that need to be in place in order to work with various pathogenic organisms.
These biosafety levels range from 1 (least likely to cause harm to an individual) to 4 (most
harmful and infectious) [24]. The basis for these biosafety measures are derived from the WHO,
which, in turn, base their recommendations upon the availability of effective preventive
measures and treatment options [25]. As the biosafety level of a pathogen increases, it is
necessary to increase the safety measures for a person working in these conditions. In the
research laboratory setting, M. tuberculosis is considered a biosafety level 3 (BSL3) pathogen;
a BSL3 pathogen is defined by the WHO as one that poses a high risk for an individual but a
low risk for the community and can cause serious harm to an infected human. The various
safety measures that must be put in place include laboratory practices, facility construction,
security, and safety equipment. The exact nature of the measures put in place will vary slightly
from facility to facility but in general, this includes separate rooms and equipment for work
with the pathogen. Rooms in which the pathogen is manipulated must be under negative
pressure so that airflow is directed from a clean room into a ‘dirty’ room to prevent it from
spreading. All work done with the microbe needs to be conducted in a properly outfitted
biosafety cabinet and special personal protective equipment (e.g. respirators) must be worn at
all times.
These biosafety mechanisms can be a limiting factor when attempting to study M. tuberculo‐
sis, as they require full facility involvement and specialized equipment to be in place. Addi‐
tionally, these biosafety measures, while necessary, can be relatively uncomfortable, and may
therefore limit the time with which a person can work under them. While these are obviously
not insurmountable obstacles, they should be taken into consideration before research of this
nature is undertaken.
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3.2. Slow growth of the pathogen
M. tuberculosis is a slow growing pathogen with a doubling time of approximately 24 hours
[26]. Because it grows so slowly, it is necessary to let a significant amount of time pass after
infection in order to resolve differences in vaccine treatments. If an unvaccinated mouse is
given a low dose aerosol infection of virulent M. tuberculosis, it can take upwards of 3 to 4
weeks before visible granulomatous lesions will form in the lungs [6]. When conducting
immunological research, mice are generally sacrificed 30 to 120 days after infection to examine
short and long term immunity and determine if a vaccine has had any effect on the reduction
in mycobacterial number. When the animal is sacrificed, the lungs must then be plated on
selective agar media in order to enumerate the number of mycobacteria growing in the lungs.
The time of plating the lungs until the formation of visible colonies is between 2-3 weeks. All
told, experiments of this nature often require 6-9 months of work before any data is even
collected. Therefore, when planning out experiments involving infected animals, researchers
must consider the significant amount time it will take between the initiation of the experiment
and the completion of the study.
3.3. Disease stages
As mentioned previously, infection with M. tuberculosis can be divided into distinct stages. In
humans, infection with M. tuberculosis can be divided into four stages: infection, latency,
reactivation, and transmission [5]. At each of these stages, the proteins expressed by the
organism are thought to vary significantly and therefore protection in one stage may not
protect in all. After primary infection, in an immunologically healthy individual, an infection
will progress to a latent TB infection (LTBI). The persistence of infection despite no active
disease in a clinically ‘cured’ individual, make end point goals difficult to define for a re‐
searcher developing a vaccine [16]. There is significant evidence that sterile clearance of M.
tuberculosis is a rare occurrence and rather, it is the maintenance of an active immune system
to contain the mycobacteria in the latent state that prevents active disease from forming [1,
27]. In most individuals, this is where the infection will remain unless there is an outside
occurrence that reduces the functionality of their immune system [1]. A person with a LTBI
will not have active disease, but will have developed memory cells against M. tuberculosis
antigens. It is generally believed that when M. tuberculosis is in a latent stage it is slow growing
or non-replicative and most likely expresses a different set of antigens than during the primary
infection stage of the life cycle [1]. The exact immunological events that are required in order
for the pathogen to progress from latency into an active state are incompletely understood.
The immune response that humans develop against M. tuberculosis infection appears to contain
the bacteria and induce it into a latent stage, yet fails to sterilize the infection [5]. This leads to
some interesting questions as to what types of antigens to target for vaccine development.
When a person has a LTBI, their immune system is effectively containing the mycobacteria
and they do not get sick. Do we therefore design vaccines to elicit an immune prolife similar
to someone with a latent infection even though that profile is not sufficient to eliminate the
pathogen? It is interesting to note that individuals that are infected with M. tuberculosis and
progress on to latency are not protected from re-infection. However, because detection of M.
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tuberculosis when it is in a latent stage is quite difficult with our current diagnostic methods,
it is often challenging to distinguish between reactivation of the primary (latent) infection or
re-infected from a new exposure [1, 16]. Since our understanding of the possibility of lung
sterilization post-M. tuberculosis infection is incomplete, the comparison of persons with LTBI
to those with active disease is limited in what it can tell us about protective immunity.
Ideally,  the best vaccine would be one that provides protection from all  stages of infec‐
tion,  i.e.  a  vaccine must be effective against  primary infection,  latency,  reactivation,  and
reinfection [1, 2].
3.4. Vaccination in immunocompromised individuals
Of the estimated 1.3 million people who died of TB in 2013 around 25% of them were co-
infected with HIV [3]. In fact, TB is the number one killer of HIV infected individuals [7, 28-30].
The resurgence of M. tuberculosis infections in the 1990s has largely been attributed to the
advent of the HIV epidemic [30, 31]. The reasons behind the increased susceptibility of HIV
infected individuals to M. tuberculosis infection are not completely understood. An infection
with HIV leads to a reduction in CD4+T cells and this is believed to be the cause of greater
susceptibility to M. tuberculosis by most individuals [28, 30, 32]. One hypothesis is that HIV
disrupts the function of the granuloma and allows for the replication of the organism [28]. The
immune system of an HIV infected individual is, therefore, not able to control or contain the
M. tuberculosis infection, resulting in reactivation of the disease [28, 30]. HIV infection may also
disrupt the function of macrophages and M. tuberculosis specific T-cells that prevents the killing
of the pathogen [28]. An interesting aspect of the M. tuberculosis-HIV co-infection is that HIV
infection leads to susceptibility to M. tuberculosis even after anti-retroviral therapy has
commenced and CD4+T cell counts have been restored to normal [33] [30, 34]. It has also been
found that HIV infected infants do not produce a robust T helper (Th)1 immune response when
vaccinated with BCG [30]. Additionally, HIV positive infants are at a significantly increased
risk of dissemination of BCG after vaccination [7, 15, 16].
Another group of immunocompromised individuals that must be considered are those with
poor living conditions and poor nutrition. TB is a disease of the poor and mainly affects those
who are already at a socioeconomic disadvantage. Poor nutrition and living conditions
increases a person’s susceptibility to disease and dampens their immune response to a
challenge. These living conditions could impair the ability of the immune system to respond
properly both to a vaccination and exposure to a pathogen. Other conditions, such as diabetes
or vitamin D deficiency, can also impair the ability of the immune system to produce a robust
response and indeed, both conditions have been associated with an increased risk for devel‐
oping TB [35-37].
3.5. Vaccination post exposure to the pathogen
In the case of TB, it is important to consider if the vaccine is aimed at pre or post-exposure to
the pathogen. As mentioned in the previous section, a person’s immune system will respond
differently to a vaccine if they have already been exposed to the pathogen. Since the immune
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system will have already been primed to respond to particular M. tuberculosis antigens that are
not capable of protection, it is necessary to find a new method of immune activation. Because
of the high prevalence of M. tuberculosis in endemic countries, it is likely that in order to
eradicate TB, a vaccine will need to be effective post-exposure.
3.6. Laboratory strains versus clinical isolates
Mycobacteria from clinical isolates are often quite different than the strains commonly used
in laboratory practice. Laboratories, by necessity for the repeatability of their experiments,
must maintain an unchanging common lab strain. There are currently several strain types used
in laboratories throughout the world (H37Rv, HN878, Erdman, CDC1551, etc.) that vary in
their virulence and antigenic composition. Variation can also occur within a strain depending
on how it is handled in the laboratory. Unfortunately, however, these strains can be signifi‐
cantly different than the mycobacteria isolated from infected patients. The mycobacteria found
‘in the wild’ is going to be constantly changing and mutating depending on various selection
factors. The extent of the divergence between laboratory strains and clinical isolates will
depend upon the strength of the selection factor. These selection factors can include incomplete
drug treatments or the strength of a non-drug treated person’s immune response to the
pathogen. Additionally, there is a natural mutation rate for the genome of all organisms
independent of selection factors due to DNA replication errors or un-repaired DNA damage.
The selection factors and mutational changes observed in clinical isolates are most apparent
with the emergence of multi, extreme, and totally drug resistant organisms. While it is hoped
that there is enough similarity between laboratory strains and the clinical isolates that
vaccination against one will provide protection from all forms of M. tuberculosis, the constant
mutation of wild-type strains should be considered.
3.7. Intrinsic properties of M. tuberculosis which make it difficult to immunize against
Currently, almost all vaccines that have proven to be efficacious in humans against infectious
pathogens convey protection through the production antibodies [1, 38]. These antibodies will
coat a pathogen and signal to the immune cells that it should be removed from the system. M.
tuberculosis, however, is intracellular, which means that the immune system must be able to
recognize and then eliminate infected host cells without causing excessive damage to the host.
M. tuberculosis has established several methods by which it can evade recognition by the host
immune system. Most of these mechanisms revolve around ways of keeping the pathogen in
a quiescent state within the macrophage. For example, the recruitment of professional
phagocytic cells to the site of infection provides an increased number of ideal environments
for M. tuberculosis survival. Once phagocytic cells have taken up the organism, it can survive
within macrophages by arresting and inhibiting the maturation of the phagosome to prevent
its own clearance from the cell [37]. These blocks in phagosome maturation prevent fusion of
the phagosome with the lysosome and acidification of the compartment and thus elimination
from the cell [37]. This block in phagocytosis also prevents proper presentation of M. tubercu‐
losis antigens [1]. Presentation of antigens is essential for recognition that an antigen is foreign
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and needs to be eliminated, as well as for the creation of immune memory. M. tuberculosis also
evades removal by the ability to regulate both the necrotic and apoptotic death of host cells [5].
All of the elimination avoidance methods developed by M. tuberculosis serve to maintain the
pathogen within the macrophages where it can live for decades as a latent infection [1, 37].
While M. tuberculosis infection does produce an immune response in the host, this response
fails to result in protection or complete clearance of the pathogen [1, 5]. Therefore, when
designing a vaccine, it is necessary to activate the immune system in such a way that the host
can overcome these evasion methods and recognize that the pathogen infected cells should be
destroyed.
4. Animal models used for vaccine development
In some cases where the pathogen is non-lethal or there are readily available treatment options
(such as malaria or influenza), it is possible to test the efficacy of a vaccine in a human model.
In these instances, a willing volunteer is vaccinated, and then exposed to the pathogen by the
researcher in a controlled manner [16]. In the case of M. tuberculosis however, this course of
experimentation is unethical as it is still controversial if sterilization of the lungs post-infection
is even possible. It is therefore imperative that we use animal models for the development of
vaccines. A vaccine is considered efficacious in an animal model if it is able to reduce the
number of colony forming units (CFU) in the lung. Currently, the goal for new vaccines is to
reduce the number of CFU in the lung better than BCG, which consistently provides around
a 1 log10 CFU reduction in the mouse model of tuberculosis.
4.1. Mouse model
4.1.1. Advantages
Cost effectiveness and scalability. One of the biggest reasons for the use of mouse models in
research is their cost effectiveness. With the exception of highly specialized knock-in or knock-
out models, inbred mice can be purchased in large numbers at very low cost. Since mice can
often be housed with multiple animals per cage, this further reduces the facilities cost by
utilizing less space per animal. A researcher can therefore scale a study up to a magnitude that
would be impossible with larger or more costly animals.
Inbred mouse strains and genetically modified models. Through the use of genetically identical
inbred strains, researchers from all over the world have the ability to collaborate using the
same set of tools and more effectively build upon previous studies. The ready availability of
facilities like The Jackson Laboratories and Charles Rivers, which specifically maintain these
inbred mouse strains are an invaluable resource for researchers. These facilities also make it
easy to custom order genetically modified mouse models to test the importance of various
proteins during vaccination or pathogen challenge. The availability of total or conditional
knock-out mice, as well as knock-in models, allows researchers to effectively use in vivo system
to ask questions that are unavailable by other methods.
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Availability of immunological reagents. The use various molecular assays after completion of an
animal experiment can provide vital information about the function of the immune system.
An additional advantage to using the mouse model is that because it is so widely used, reagents
are available for many types of immunological assays. In particular, antibodies for western
blot, enzyme linked immunosorbent assays (ELISAs), flow cytometry, and many others, are
commonly used on mouse models and are therefore relatively easy to optimize for a particular
experiment.
Susceptibility of various strains. The strain of mouse that will be used for an experiment is of
great importance when designing an experiment. There is significant variability between
mouse strains as to their susceptibility to TB infection. This variance in susceptibility of a mouse
strain can depend up on several important factors including the route of infection, the dosage,
and the strain of M. tuberculosis [39]. While genetic modification is commonly done on a C57Bl/
6 background, these mice are actually resistant to M. tuberculosis infection and aerosol infection
does not reduce their lifespan [39]. Some strains such as CBA are very susceptible to infection,
while others, such as the BALB/c, appear to be susceptible depending on the route of infection
[39]. These last two strains, however, do have the disadvantage that there are fewer genetically
modified strains available with this background. The immune systems of both the susceptible
and resistant strains clearly respond differently to both vaccination and challenge infection
and therefore, it is often useful for researchers to test a vaccine in more than one mouse model.
4.1.2. Disadvantages
A major disadvantage of the mouse model is that the immune system is not the same as that
of a human. The underlying genomic inflammatory response to infection in a mouse has been
shown to bear little correlation to what occurs in humans [40]. Many drugs that have been
designed to modify inflammatory responses in mice, have failed human clinical trials [40].
While humanized mice (a mouse containing human genes, cells, or tissue) may allow for an
immune response closer to that of a human, it is impossible to create an identical response.
Additionally, unlike in humans, BCG vaccination of a mouse model does convey some
protection from M. tuberculosis infection and reduces the number of CFU in the lungs. A better
understanding of the critical cellular differences between the mouse and human immune
system is needed before we can effectively translate studies from the bench to the clinic.
4.2. Guinea pig model
4.2.1. Advantages
Historically, the guinea pig was the first animal model used for tuberculosis research. Guinea
pigs are considered the gold standard by which M. tuberculosis vaccines are tested before
continuing to larger animal models or even humans. This is because guinea pigs have an
immune response that more closely resembles that which is seen in susceptible humans.
Guinea pigs are very susceptible to infection and demonstrate a tuberculosis disease progres‐
sion that is similar to that seen in humans [41].
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One aspect of guinea pig research that is both an advantage and a disadvantage is the lack of
in-bred laboratory strains. There are only a handful of laboratory guinea pig strains available
commercially and these are mostly out-bred stock that will not be genetically identical at every
locus. This provides greater genetic diversity within an animal strain with which to tests
vaccine efficacy. Obviously when vaccines move into human trials, genetic diversity will be
unavoidable (as mentioned previously), and therefore the guinea pig provides a more realistic
model of what will happen in humans. However, this does limit the exact repeatability of an
experiment due to the lack of genetically identical animals.
4.2.2. Disadvantages
A disadvantage of the guinea pig model is that they are very susceptible to infection, but
humans are relatively resistant. While the phenotype observed during disease progression
does resemble that of humans with active disease, this represents only a small fraction of people
infected with M. tuberculosis. It is believed that most humans are resistant to infection and will
not go on to active disease unless an outside force reduces their immune response and ability
to contain infection in a latent state [6, 7]. The exact mechanisms behind reactivation of latent
M. tuberculosis are not completely understood, but it is a vital step in disease pathogenesis that
is missed in the guinea pig model.
The guinea pig also has the disadvantage that, because it is a larger animal, housing costs tend
to be much higher than for mice. Guinea pigs require larger cages with fewer animals per cage
and thus facility space limitations may reduce the number of animals included in a study.
Additionally, because they are not as commonly used as the mouse model, it is more difficult
to find the facilities and veterinary expertise necessary to house and care for guinea pigs.
Of great importance is the lack of genetically modified guinea pig models for the researcher
to use. This can severely limit the ability of the researcher to develop and improve upon vaccine
models.
4.3. Other animal models
The mouse and guinea pig are the most commonly used animal models for research into M.
tuberculosis vaccine development. However, there are several other animal models that are also
sometimes utilized for this purpose including rabbit, cattle, non-human primates (NHP) and
even zebrafish [42-44].
Macaques are an NHP that are a promising model to use for the development of a tuberculosis
vaccine. The pathophysiology of TB infection in a macaque closely resembles that of what
occurs in human populations, including latency – an aspect of infection that has been difficult
to model in other animals [43, 45]. Due the size of the animals, their limited availability, the
cost of housing and care, as well as ethical considerations, use of NHP, while highly informa‐
tive, is extremely limited and generally only done after a vaccine has been tested in smaller
animal models.
One of the biggest disadvantages to use of any of these non-mouse models is that there are
very few reagents available for post-mortem tissue analysis. Few antibodies or other com‐
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monly used immunological reagents are available for the study of the immune response in
many animal models. Sometimes there is enough overlap in antigens between mouse and
humans and other animals that some tests can be conducted, but this is a fairly rare occurrence.
While these are not limitations that preclude the use of non-mouse animal models, it does limit
the information that can be acquired from using them [46]. There is therefore a huge need to
expand our animal model base beyond just the mouse. Genetic evaluation of and the ability
to produce inbred strains of other animal models would be an unbelievable advantage to all
clinical research beyond just tuberculosis vaccine development.
We can garner important information from all of these animal models and it is clear that their
use is absolutely essential for progress in medical researcher to be made. However, it must be
remembered that these models are imperfect and there are scientific limitations to the results
from studies using them. For instance, in a laboratory setting, animals tend to be exposed only
once and to only one strain of pathogen. We know this will not be the case for humans since,
as discussed above, M. tuberculosis is constantly mutating and in endemic regions a person will
likely be exposed to several different strains at multiple times throughout their life [47].
Ultimately, the only way to test out if a vaccine will be effective in a human population is to
actually test it in a human population. While it is certainly possible to move on to human trials,
there are many steps that must be undertaken before a vaccine can be put into widespread use.
This process will be discussed in the next section.
Another important question to consider when examining results from animal models is if we
are missing vaccines that would be highly efficacious in a human, but discarding them because
they do not act well in our animal models. This is a problem for all areas of clinical research
and is, unfortunately, unavoidable given our current knowledge. The only way to overcome
this limitation is for research to continue to close the gap in our understanding of how animal
and human immune systems differ. The continued refinement of our animal models will
provide us with the tools necessary to produce an effective vaccine. This is another reason why
the use of multiple animal models is often needed in order to improve the translatability of
the research. Most animal models recapitulate some, but not all, aspects of the human features
of a disease. If multiple animal models are tested, it increases the likelihood of finding a vaccine
that will work in humans.
5. The future of M. tuberculosis vaccine development
There is a profound lack of understanding about what exactly a good immune response to M.
tuberculosis infection actually looks like. This is due, in part, to our limited information about
how the immune system contains infection in a latent state as well as how it can revert to active
disease. Because our knowledge is incomplete, it complicates decisions regarding which
vaccine candidates to pursue in animal models. Our best vaccine, BCG, is not 100% effective
in killing off M. tuberculosis in a mouse despite eliciting a strong Th1 immune response that is
thought to be necessary to produce immunity against the pathogen [1]. In general, if a new
vaccine candidate can also elicit a strong Th1 response in a mouse model, it will then move on
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to challenge studies where an animal model is immunized, then infected. While it is clear that
protection from infection does require strong T cell immunity, it is also clear that that form of
immunity is not sufficient to prevent disease. Sometimes, even when a vaccine candidate is
promising in preliminary trials, this will not lead to protection when challenged with infection.
This is why many of the vaccines currently in the approval process pipeline have multiple
pathways by which they induce an immune response. The hope is that one of these other
pathways, or a combination of various pathways, will give us more and better information
about what immunological protection would look like [1].
There are at least 12 new vaccines candidate that have entered the pipeline for efficacy and
safety testing and are the first to be put through the approval process in over 100 years [2, 48].
It is encouraging to note that there are so many vaccines being tested as it increases the
likelihood of finding a formulation that will be effective. The arrival of these new vaccines,
even those that fail, is a promising step forward in our understanding of immunity and what
protection will look like. In this section we will discuss some of the characteristics of these
vaccines as well as the steps that must be gone through before they can be put into widespread
use.
5.1. Common tactics taken for vaccine development
There are two main tactics for the development of a new vaccine against M. tuberculosis
infection. The first is the prime-boost or enhancing the efficacy of the existing vaccine, BCG.
In this approach, an individual can be given an adjuvanted vaccine at the same time or at a
specified period of time after BCG vaccination. The other tactic is to develop a whole new
vaccine that is given instead of BCG. There are advantages and disadvantages to both strategies
and a discussion on the ethics of trial design for both of these can be found in the next section.
Many of the vaccines that are being developed contain one or more of a select group of antigens
for the initiation of an immune response. Antigen 85A/B (Ag85A/B) and the 6kD early secreted
antigenic target (ESAT-6) are proteins that are commonly included in a vaccine make up [2].
Ag85A/B are M. tuberculosis surface proteins that are involved in bacterial cell wall biosynthesis
and elicit an immune response in animal models [23]. ESAT-6 is a secreted protein critical for
virulence that is not found in BCG and can also stimulates a strong immune response [18, 49].
These proteins, along with several others that have been found to be immunogenic, have been
put into various formulations and are currently being tested.
In addition to multiple combinations of proteins found to be immunogenic, there has also been
testing of which delivery route will provide the best protection. For instance, some vaccines
provide better immune protection if they are delivered via aerosol route rather than through
intradermal injection. Therefore, many studies are being conducted looking at both multiple
delivery routes as well as vaccine make-up.
5.2. Ethical considerations
There are also important ethical considerations that must be addressed when developing a
new vaccine. When testing out a vaccine, it is important to consider the health and safety of
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the control groups as well as those receiving the novel vaccine. For instance, if you have in
your possession a vaccine (i.e BCG) that conveys at least some protection against TB, you
ethically cannot withhold access to that vaccine simply because you need a placebo control
group for your research study. Additionally, a researcher attempting to test out an entirely
new vaccine must also consider the possibility that their vaccine will not work and therefore
those test subjects are at an increased risk of developing disease. While there are ways to
circumvent these issues and still produce an ethically sanctioned and scientifically sound
vaccine trial, it does require additional preparation and manpower to execute. Because of these
significant ethical complications, however, much of the recent research into TB vaccines has
been for the development of adjuvants to boost BCG rather than to develop completely new
vaccines.
5.3. MVA85A
The most notable of these new vaccines is MVA85A, which is the first modern day M.
tuberculosis vaccine to reach an efficacy trial. MVA85A is a Modified Vaccinia virus Ankara
that has been engineered to express Ag85A [1, 50]. In animal models, MAV85A was shown to
produce a strong Th1 response and provide better protection against M. tuberculosis infection
than BCG [47, 51-53]. It was designed as a prime boost, to enhance the efficacy of BCG, by
giving it to infants a few months after BCG vaccination. In a Phase 2b clinical trial, MVA85A
was found to be quite safe and did produce an immunogenic response, but unfortunately, did
not provide better protection against infection than BCG alone [53]. This was despite earlier
findings that MVA85A induces the immune responses believed to be necessary for protection
[54]. In fact, this (previously assumed to be beneficial) CD4+T cell response to Ag85A is still
detectable in individuals given MVA85A up to 6 years after vaccination [55]. Even though
MVA85A did not provide the protection that was hoped, there are some promising indications
that this vaccine may be useful in other settings. For instance, the authors suggest that this
vaccine maybe beneficial in preventing the spread of disease in adults rather than in infants
[53]. Clearly further testing of the MVA85A vaccine needs to be conducted. Even though initial
results with MVA85A were disappointing, it does represent a promising step in vaccine
development. Given the state of the field, any knowledge gained about immunity against M.
tuberculosis, even if negative, can provide useful information and guide future studies
5.4. Vaccine approval process
The WHO offers a set of guidelines for the approval of a vaccine, and many countries adopt
these standards or use them as a basis for their own set of regulations. The point of these
regulations is to do as much as possible to ensure the safety and efficacy of the vaccine before
it is put into widespread use. In the United States, the Federal Drug Administration (FDA)
regulates and oversees the approval process for the development of all vaccines. This discus‐
sion will give a quick overview of the FDA regulations specific to the US as an example of what
must be undertaken before a vaccine is approved for use. The FDA approval process involves
an exploratory stage, a pre-clinical stage, an Investigational New Drug (IND) application, and
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finally a three phase clinical trial in human subjects [56]. The FDA has the authority to stop a
vaccine trial at any point if safety becomes a concern.
The exploratory stage is the basic science side of the vaccine development process. It is in this
stage where researchers investigate the potential of various antigens to induce an immune
response and are frequently done in vitro although some in vivo studies may be conducted.
This is where the formulation of the vaccine is first tested and the identification of immuno‐
genic proteins is determined.
The pre-clinical stage involves animal model testing of the various antigens that were discov‐
ered in the exploratory stage. In this stage, animals are immunized using a new antigen or
vaccine make up and then challenged with M. tuberculosis infection. The various animal models
discussed in the previous section are used in this stage of vaccine development. In order for
the vaccine to move on to humans, it must first demonstrate efficacy in multiple animal models.
The animal models used can vary depending on pathogen, but for M. tuberculosis these models
generally include (in order), mouse, guinea pig, and non-human primates. Once a vaccine has
been found to be effective, it must pass toxicology and distribution studies in the animal
models, as well as demonstration of the ability to produce the vaccine in a lab with Good
Manufacturing Practice (GMP) certification [57]. After the completion of these studies an IND
application is submitted and, upon approval, human clinical trials will commence.
Phase 1 clinical trials are small studies designed to test the safety and immunogenicity of the
vaccine. Phase 2 clinical trials are larger and used for further refine dosage and efficacy of the
vaccine as well as determining what population it can be most effectively used on. Phase 3
clinical trials involve thousands of individuals and require additional safety documentation
to complete [56].
Once all of these stages have been completed, a cross-disciplinary committee from the FDA
must then approve a lengthy Biologics License Application (BLA). The BLA will include not
only safety and efficacy information but also guidelines for the mass manufacture and
distribution of the vaccine as well. As may be obvious from this brief description, the process
of vaccine approval can be quite lengthy and will often last 10-15 years. The enormous cost
associated with undertaking such an endeavor often requires the collaboration of both private
and public funds at multiple institutions in order to be completed.
6. Conclusions
The development of a vaccine against M. tuberculosis has been one of the hardest puzzles facing
immunologist for the past century. When examining an infection and an appropriate immune
response, the traditional approach, at least in relation to tuberculosis research, has been to try
to amplify the immune response of a healthy person in order to clear the bacteria. However,
is this really the approach we should take when examining M. tuberculosis? In the case of M.
tuberculosis infection, is it the body’s very own defense mechanisms that is causing lung tissue
damage and forcing the mycobacteria into a latent stage? Is the body’s response to infection
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actually a good thing or is it contributing to disease progression because it creates an envi‐
ronment that harbors the bacteria (a granuloma) rather than eliminating it? Should we instead
be attempting to induce activation of a whole new pathway in order to sterilize the lungs?
The urgency to find of an effective vaccine is nowhere as apparent as the emergence of drug
resistant tuberculosis that been appearing with increasing frequency in the last decade. The
currently available drugs are expensive and require a lengthy course of treatment; increasing
the likelihood of non-adherence by sick people and therefore increasing the possibility of even
more resistant strains evolving. Because a person does not naturally develop immunity to the
pathogen when they are infected, they can become re-infected if they are exposed to the
pathogen a second time and have to endure the same drug regimen as before. Only by
providing continuous, protective immunity against recurrent infection can we hope to
eradicate this devastating disease from the population.
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